Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
IPO Year: 2019
Exchange: NASDAQ
Website: harpoontx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/5/2024 | $23.00 | Outperform | Oppenheimer |
| 11/20/2023 | Outperform | TD Cowen | |
| 7/6/2022 | $16.00 | Buy | Canaccord Genuity |
| 11/11/2021 | $25.00 → $19.00 | Outperform | SVB Leerink |
| 9/28/2021 | $16.00 | Neutral → Buy | Citigroup |
| 8/6/2021 | $29.00 → $25.00 | Outperform | SVB Leerink |
Seismic Therapeutic, Inc., the machine learning immunology company, today announced that Julie Eastland has been appointed as Independent Director to Seismic's Board. Ms. Eastland brings more than 30 years of experience in finance and strategy in clinical stage biotechnology companies delivering novel therapeutics to patients with unmet needs in oncology and immunology. "It is with much excitement that we welcome Julie to our Board of Directors. As a proven independent Director and executive with decades of experience in the biopharmaceutical industry, Julie brings deep knowledge across the company growth and drug development continuum, from discovery through commercialization," said Jo Vi
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (NASDAQ:HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon's common stock will no longer be publicly traded or listed on the Nasdaq Stock Market. "We continue to augment and diversify our oncology pipeline with innovative approaches to help people with cancer worldwide," said Dr. Dean Y. Li, president, Merck Research Laboratories. "We are ple
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. (NASDAQ:HARP) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240108498651/en/ "At Merck, we continue to enhance our onc
James Bucher, J.D. joins as Chief Legal Officer Wendy Chang promoted to Chief People Officer SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of James Bucher, J.D. as Chief Legal Officer, and the promotion of Wendy Chang, to Chief People Officer. Mr. Bucher and Ms. Chang are part of the executive management team and report directly to the Chief Executive Officer. "I am delighted to welcome Jim to the Harpoon leadership team and announce Wendy's promotion. I look forward to benefiting from Jim's extensive experience as we contin
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) being held in San Francisco, CA and virtually on January 25-27, 2024. HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon's proprietary Tri-specific T cell Activating Construct (Tri
• HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure to BCMA-targeted therapy • At the 12 mg dose, cohorts demonstrated favorable activity and safety profile:- 63% ORR; with 53% VGPR or better -- CRS reported in 16% of patients, no Grade 3 events, no ICANS - • Findings support further clinical development at the 12 mg RP2D SOUTH SAN FRANCISCO, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported data from the Phase 1 study of HPN217 in
October 2023 financing funds late-stage clinical trials of HPN328 in multiple tumor types Positive interim results from Phase 1/2 trial of T cell engager HPN328 in patients with small cell lung cancer (SCLC) and other neuroendocrine tumor types presented at ESMO 2023 HPN328 Phase 2 monotherapy dose(s) selection on track for year-end 2023 for discussion with regulators in 1H 2024 Data update of ongoing HPN328 Phase 1/2 trial expected in 1H 2024 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP) (the "Company"), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the third quar
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and upcoming oral presentation of the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma. The oral presentation will take place at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego. Details of the ASH presentation are as follows: Title: Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN21
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP) (the "Company"), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a securities purchase agreement for a private placement in public equity ("PIPE") financing that is expected to result in upfront gross proceeds of approximately $100 million, with up to an additional approximately $50 million of gross proceeds upon cash exercise of warrants, before deducting placement agent fees and offering expenses. The PIPE financing was led by a leading biotechnology investor associated with one of the largest alternative asset managers,
Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete responses 32% (6/19) confirmed response rate in patients with small cell lung cancer (SCLC), including one confirmed complete response42% (5/12) confirmed response rate in other neuroendocrine tumor types, including two confirmed complete responses Generally well tolerated; cytokine release syndrome (CRS) most common, predominantly low-grade, with no Gr3 CRS in 1 mg priming dose cohorts Enrollment in monotherapy dose cohorts nearing completion, on track to select Phase 2 dose(s) by end of 2023Results will be presented in a poster session at ESMO
Seismic Therapeutic, Inc., the machine learning immunology company, today announced that Julie Eastland has been appointed as Independent Director to Seismic's Board. Ms. Eastland brings more than 30 years of experience in finance and strategy in clinical stage biotechnology companies delivering novel therapeutics to patients with unmet needs in oncology and immunology. "It is with much excitement that we welcome Julie to our Board of Directors. As a proven independent Director and executive with decades of experience in the biopharmaceutical industry, Julie brings deep knowledge across the company growth and drug development continuum, from discovery through commercialization," said Jo Vi
James Bucher, J.D. joins as Chief Legal Officer Wendy Chang promoted to Chief People Officer SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of James Bucher, J.D. as Chief Legal Officer, and the promotion of Wendy Chang, to Chief People Officer. Mr. Bucher and Ms. Chang are part of the executive management team and report directly to the Chief Executive Officer. "I am delighted to welcome Jim to the Harpoon leadership team and announce Wendy's promotion. I look forward to benefiting from Jim's extensive experience as we contin
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the appointment of Haibo Wang as Senior Vice President of Business Development. Mr. Wang brings 15 years of biopharma business development, finance, and mergers and acquisitions (M&A) transaction experience to Harpoon. "We are pleased to welcome Haibo as Senior Vice President of Business Development at Harpoon," said Julie Eastland, President and CEO of Harpoon Therapeutics. "Haibo's extensive experience and strategic acumen will play a pivotal role in driving our business growth and forging impa
Biopharma executive with more than 20 years of global corporate, business development, and commercial strategy experience to join Replicate leadership team SAN DIEGO, July 10, 2023 /PRNewswire/ -- Replicate Bioscience, a company pioneering novel self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease, and more, announced today that it has appointed Rachael Lester as its Chief Business Officer. Ms. Lester, who has more than 20 years of experience as a senior executive in the biopharmaceutical industry, will be responsible for leading corporate strategy, business development, portfolio strategy, and new product planning.
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Luke Walker, M.D., as Chief Medical Officer. Dr. Walker will lead the clinical development strategy and its execution for Harpoon Therapeutics and the product candidates derived from the company's multiple technology platforms. Dr. Walker will report to Julie Eastland, Harpoon Therapeutics' President and Chief Executive Officer, and his appointment was effective October 3, 2022. "I'm excited to join Harpoon Therapeutics and work alongside science-driven, collaborative colleagues,
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Lauren Silvernail to its Board of Directors and as the Chairperson of its Audit Committee. "We welcome Lauren to our Board of Directors. Her strategic, operational and financial experience in the life sciences industry will be a strong addition," said Julie Eastland, President and Chief Executive Officer of Harpoon Therapeutics. "We look forward to Lauren's guidance as we continue to execute our business plan and advance our novel class of T cell engagers in clinical trials." L
Appointments named for two key executive leadership positions in human resources and translational medicine SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Wendy Chang to Senior Vice President, Human Resources and Banmeet Anand, Ph.D., to Senior Vice President, Translational Medicine. Both Ms. Chang and Dr. Anand bring deep experience to their respective roles, enhancing strategic and scientific guidance within the organization to drive the company forward in a year of anticipated clinical advancements across Harpoon's portfol
Regulatory News: Sensorion (PARIS:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces the appointment of Scott D. Myers as Chairman of its Board of Directors and Independent Director. Scott, who also serves as Chairman of the Board at Dynavax Technologies (NASDAQ:DVAX) and Harpoon Therapeutics (NASDAQ:HARP), brings almost 30 years of global experience in the pharmaceutical and medical technology industries to Sensorion. Previously, Mr Myers served as the Chief Executive Officer and Director of AMAG Pharmaceuticals, Inc (NASDAQ:AMAG), where h
SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Alan Colowick, M.D., to its board of directors. Dr. Colowick is an experienced biotech leader and has served in numerous executive and board roles. “We are thrilled to welcome Dr. Colowick as the newest member of the Harpoon Board of Directors,” said Ron Hunt, Chairman of the Board of Directors of Harpoon Therapeutics. “Alan is an accomplished industry leader who has managed and served on the boards of numerous innovative life science companies and he brings extensi
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma77% (10/13) objective response rate (ORR) observed across highest doses (12 and 24 mg) Responses were durable, with many patients on treatment longer than a yearGenerally well-tolerated with a low incidence of cytokine release syndrome (CRS): Low-grade CRS in 29% of patients across highest step dose regimens; 95% of events occurred following first or second dose; no Grade 3 or higher CRS Dose and schedule optimization is ongoing; maximum tolerated dose not yet reached in step dose regimenManagement to host webcast and conference call to review
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a conference call and webcast to review updated interim results of its Phase 1 HPN217 clinical program presented at the 64th American Society of Hematology (ASH) Annual Meeting and provide a corporate update. The live call/webcast will take place at 4:30 p.m. ET / 3:30 p.m. CT / 1:30 p.m. PT on December 12, 2022 and can be accessed by dialing 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers with conference ID code number 13734677. A webcast of the l
Compelling initial clinical activity for HPN328 (DLL3) and HPN217 (BCMA) targeting programs observed in escalation phase of ongoing trialsEncouraging profile of tolerability and activity seen at higher doses in both HPN217 and HPN328; low grade CRS manageable, no Grade 3 CRS reported Interim data from the ongoing Phase 1/2 trial of HPN217 presented at the 2021 ASH Conference reported clinical activity at higher dose levels, including an overall response rate (ORR) of 63% and a disease control rate (DCR) of 88% in the HPN217 2150 µg/week cohort with a manageable safety profileIn the ongoing Phase 1/2 trial for HPN328, 3 out of 4 patients with small cell lung cancer (SCLC) in the two highest d
Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8 disease evaluable patients with relapsed/refractory multiple myeloma Tolerable safety profile with cytokine release syndrome (all Grade 1 or 2) observed in 9 of 37 patients (24%) Patient enrollment and dose escalation is ongoing to define the RP2D and MTD Management to host webcast and conference call to review the HPN217 data presented at ASH and provide a pipeline update on Monday, December 13, 2021 at time 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Dec. 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunothera
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a conference call and webcast to review the clinical status and provide an update on its pipeline programs. The live call/webcast will take place at 4:30 p.m. ET / 1:30 p.m. PT on December 13, 2021 and can be accessed by dialing (866) 951-6894 for domestic callers and (409) 216-0624 for international callers with conference ID code number 2760075. A webcast of the live call will be available online in the investor relations section of the Harpoon website at www.harpoontx.com. A re
15-12G - Harpoon Therapeutics, Inc. (0001708493) (Filer)
EFFECT - Harpoon Therapeutics, Inc. (0001708493) (Filer)
EFFECT - Harpoon Therapeutics, Inc. (0001708493) (Filer)
EFFECT - Harpoon Therapeutics, Inc. (0001708493) (Filer)
25-NSE - Harpoon Therapeutics, Inc. (0001708493) (Subject)
POS AM - Harpoon Therapeutics, Inc. (0001708493) (Filer)
POS AM - Harpoon Therapeutics, Inc. (0001708493) (Filer)
POS AM - Harpoon Therapeutics, Inc. (0001708493) (Filer)
S-8 POS - Harpoon Therapeutics, Inc. (0001708493) (Filer)
S-8 POS - Harpoon Therapeutics, Inc. (0001708493) (Filer)
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
SC 13G - Harpoon Therapeutics, Inc. (0001708493) (Subject)
SC 13D/A - Harpoon Therapeutics, Inc. (0001708493) (Subject)
SC 13D/A - Harpoon Therapeutics, Inc. (0001708493) (Subject)
SC 13D - Harpoon Therapeutics, Inc. (0001708493) (Subject)
SC 13D/A - Harpoon Therapeutics, Inc. (0001708493) (Subject)
SC 13G/A - Harpoon Therapeutics, Inc. (0001708493) (Subject)
SC 13G/A - Harpoon Therapeutics, Inc. (0001708493) (Subject)
SC 13G/A - Harpoon Therapeutics, Inc. (0001708493) (Subject)
SC 13G - Harpoon Therapeutics, Inc. (0001708493) (Subject)
SC 13D/A - Harpoon Therapeutics, Inc. (0001708493) (Subject)
Oppenheimer initiated coverage of Harpoon Therapeutics with a rating of Outperform and set a new price target of $23.00
TD Cowen initiated coverage of Harpoon Therapeutics with a rating of Outperform
Canaccord Genuity resumed coverage of Harpoon Therapeutics with a rating of Buy and set a new price target of $16.00
SVB Leerink reiterated coverage of Harpoon Therapeutics with a rating of Outperform and set a new price target of $19.00 from $25.00 previously
Citigroup upgraded Harpoon Therapeutics from Neutral to Buy and set a new price target of $16.00
SVB Leerink reiterated coverage of Harpoon Therapeutics with a rating of Outperform and set a new price target of $25.00 from $29.00 previously
Citigroup downgraded Harpoon Therapeutics from Buy to Neutral and set a new price target of $16.00 from $25.00 previously
Wedbush downgraded Harpoon Therapeutics from Outperform to Neutral
Cantor Fitzgerald initiated coverage of Harpoon Therapeutics with a rating of Overweight and set a new price target of $40.00
Piper Sandler initiated coverage of Harpoon Therapeutics with a rating of Overweight and set a new price target of $35.00